Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
about
Methodological challenges in measuring vaccine effectiveness using population cohorts in low resource settingsGlobal, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.The epidemiology of all-cause and rotavirus acute gastroenteritis and the characteristics of rotavirus circulating strains before and after rotavirus vaccine introduction in Yemen: analysis of hospital-based surveillance data.Systematic review of the economic value of diarrheal vaccinesVaccines against human diarrheal pathogens: current status and perspectivesEconomics and financing of vaccines for diarrheal diseasesCost effectiveness of a pentavalent rotavirus vaccine in OmanImpact and cost-effectiveness of rotavirus vaccination in BangladeshA cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines.High-risk enteric pathogens associated with HIV infection and HIV exposure in Kenyan children with acute diarrhoeaRota Viral Infection: A Significant Disease Burden to Libya.Rotavirus group A genotypes detected through diarrheal disease surveillance in Haiti, 2012.The Economic Burden Attributable to a Child's Inpatient Admission for Diarrheal Disease in Rwanda.Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis.Determinants of household costs associated with childhood diarrhea in 3 South Asian settings.The use of cost-effectiveness analysis for pediatric immunization in developing countriesImportance of cholera and other etiologies of acute diarrhea in post-earthquake Port-au-Prince, Haiti.Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome.Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: regional analysis and assessment of major determinants.World Health Organization perspectives on the contribution of the Global Alliance for Vaccines and Immunization on reducing child mortality.Rotavirus vaccines contribute towards universal health coverage in a mixed public-private healthcare system.Conquering rotavirus: from discovery to global vaccine implementation.Rotavirus infection.Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors.Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.Seven great achievements in pediatric research in the past 40 y.Enhancing viral vaccine production using engineered knockout vero cell lines - A second look.Epidemiological Survey of Rotaviruses Responsible for Infantile Diarrhea by the Immunomolecular Technique in Cotonou (Benin, West Africa).
P2860
Q26800157-B575C1C8-D728-4333-A14D-843BBA2369ECQ30410700-AD51B07A-022E-4E6D-BCE9-FC75CD187FFAQ31004836-E07A28A2-BF4D-47B1-A94D-8112C24F3AEFQ33577996-6A1A9504-F744-49AB-969E-E6CA9D71D235Q33578045-8CEC20F6-7A86-4A6E-9CF3-D0AE28B55C3EQ33578052-EF68EC02-6B6C-4285-85C2-03524B61873DQ33835633-00472612-8695-49B9-9F5D-CFD4820A8115Q33907724-CAEB069D-FDD7-4535-9B59-DC03CA4273B1Q34463522-6CC4C665-9C2A-402D-8429-0BC28DE1969CQ35136908-3871654C-78DF-45C5-8D66-44F43BC80B3DQ35639111-0FE007A4-342B-4898-A12A-F2737CD5FD7EQ35836667-B0780910-48B7-4381-9DBB-B9A91F5ABC57Q35930760-BEA4EF6D-B9A2-451E-AC19-4419C1E6507FQ36294177-CEBF8286-7016-405E-BAEE-4B429BD4213DQ36412073-2A957ECB-872D-4B8A-8C59-465B744F45AAQ36490234-387D18E6-5E9B-4142-B18B-2AF5E62B2758Q37623286-B65C6B4F-8B7B-4459-B3F4-D43CF32F6E3CQ37694870-3AC1FB6B-0F0A-4E6F-BB5B-BC996AF23FF4Q39033442-DAA4FBEB-A52E-45D8-9F8B-92A258451395Q39051371-FBD91A36-304B-4E59-9B06-729A700494ECQ39187401-85FABCF7-7C12-4B5B-96BF-C563DC878F45Q41546108-27E18523-BD83-45D7-B9BB-A0C87D85DE3CQ46152582-654A2929-575D-4E06-A69D-A2BEE84663C4Q46614284-27E9B09F-3B1C-4ADC-A561-1CA47F847994Q47291480-AFB02B95-F72D-4E19-8ECF-03F55121AE9CQ47337788-E94A43B0-204B-4E91-B81B-7019EFA8A069Q47578662-700CFDF4-4E34-4484-85E9-671E76573F5EQ48097968-1ED5D16E-B74D-4A71-91DF-94DF6BEE453CQ52430899-1E901500-96E7-4BAE-A357-AC27DC8A0111Q54981398-C27585ED-4341-40AC-8822-1F6D3582FDF5
P2860
Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Projected health and economic ...... eligible countries: 2011-2030.
@en
Projected health and economic ...... eligible countries: 2011-2030.
@nl
type
label
Projected health and economic ...... eligible countries: 2011-2030.
@en
Projected health and economic ...... eligible countries: 2011-2030.
@nl
prefLabel
Projected health and economic ...... eligible countries: 2011-2030.
@en
Projected health and economic ...... eligible countries: 2011-2030.
@nl
P2093
P1433
P1476
Projected health and economic ...... eligible countries: 2011-2030.
@en
P2093
Deborah E Atherly
Jacqueline Tate
Kristen D C Lewis
Richard D Rheingans
P356
10.1016/J.VACCINE.2011.12.096
P407
P478
30 Suppl 1
P577
2012-04-01T00:00:00Z